Rationale for combination therapy as initial treatment for hypertension

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Current hypertension guidelines suggest initiating antihypertensive therapy with multiple agents for patients significantly above their blood pressure goals.
• Monotherapy may be insufficient for patients with elevated blood pressure, necessitating combination therapy.
• Combination therapy can offer improved adherence and potentially fewer adverse effects compared to high-dose monotherapy.

Purpose of the Study:

• To discuss the rationale behind using combination antihypertensive therapy as initial treatment for selected patients with high blood pressure.
• To review study data evaluating the efficacy of a fixed-dose combination product versus high-dose monotherapy in managing Stage 2 hypertension.

Main Methods:

• A study involving 364 high-risk patients with Stage 2 hypertension was conducted.
• Patients received either a fixed-dose combination product (amlodipine besylate/benazepril HCl) or high-dose monotherapy (amlodipine besylate) as initial treatment.
• Blood pressure reduction was the primary outcome measure.

Main Results:

• The fixed-dose combination product (amlodipine besylate/benazepril HCl) demonstrated greater success in reducing blood pressure compared to high-dose monotherapy (amlodipine besylate).
• Initial combination therapy proved more effective in achieving blood pressure goals in this patient cohort.

Conclusions:

• Initial combination antihypertensive therapy is a rational and effective strategy for selected patients with Stage 2 hypertension.
• Fixed-dose combination products can be a valuable tool for achieving rapid and effective blood pressure control.
• Prompt achievement of blood pressure goals is crucial for improving clinical outcomes in hypertensive patients.